RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | ||||
Bulletin of Pharmaceutical Sciences Assiut University | ||||
Volume 46, Issue 1, June 2023, Page 579-595 PDF (1.18 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/bfsa.2023.301257 | ||||
View on SCiNiTO | ||||
Authors | ||||
Gehan H. Heeba 1; Mohamed Y. Abolnaga2; Eman M. Othman2 | ||||
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt | ||||
2Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, Egypt | ||||
Abstract | ||||
NAFLD is an umbrella term for a variety of illnesses of ranging severity starts with simple steatosis, develops to non-alcoholic steatohepatitis (NASH), then cirrhosis, and if not controlled, eventually can develop to fibrosis and even hepatocellular carcinoma (HCC). The disease is linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), thus addressing these interconnected disorders could be an effective approach for its management. This review gives an overview the most recent relevant research studies and the on-going therapeutic options for NAFLD focusing on the recently discovered sodium glucose cotransporter 2 inhibitors (SGLT2i), the new antihyperglycemic class of drugs which recently gained adequate popularity, as well as their efficacy and applications in experimental and clinical work. | ||||
Keywords | ||||
Non-alcoholic fatty liver disease; Sodium glucose co-transporter 2 inhibitors, Insulin resistance, oxidative stress | ||||
Statistics Article View: 154 PDF Download: 154 |
||||